ABI-274

ABI-274 is a tubulin and colchicine binding site inhibitor. ABI-274 significantly promotes cancer cell apoptosis in vitro when combined with vemurafenib (HY-12057) . ABI-274 exhibits potent synergistic efficacy in the vemurafenib-resistant xenograft model in nude mice. ABI-274 can be studied in research on melanoma[1].

Product Specifications

CAS Number

[1253697-93-6]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Microtubule/Tubulin

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

COC1=CC(C(C2=CN=C(C3=CC=C(C=C3)C)N2)=O)=CC(OC)=C1OC

Molecular Formula

C20H20N2O4

Molecular Weight

352.38

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Wang, J., et al., (2014) . Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma. Molecular cancer therapeutics, 13 (1), 16-26.